01
Causal Target Discovery
Move beyond statistical correlation. Our causal inference engine mines genomics, proteomics, and clinical phenotypes to pinpoint high-confidence targets with mechanistic evidence.
AI + Life Science
Igniting the Next Era of Drug Discovery
We fuse causal AI, generative chemistry, and systems biology to compress timelines from years to months — unlocking targets others miss, designing molecules others can't.
10×Faster Discovery
6Active Programs
41ADMET Properties
3Modalities
Vision & Strategy
From Target to Therapy, Reimagined by AI
Traditional drug discovery is slow, expensive, and prone to failure. BioIgnis applies causal reasoning on multi-omics data, generative molecular design, and pathway-level simulation to slash timelines, reduce attrition, and reveal hidden biology.
02
Generative Molecular Design
3D-aware generative models design novel scaffolds optimized for potency, selectivity, ADMET, and synthetic accessibility — simultaneously.
03
Systems-Level Simulation
Predict cascade effects, off-target risks, and synergistic opportunities across entire signaling networks — before a molecule enters the lab.
Pipeline & Milestones
Six Programs. Three Modalities. From Discovery to IND.
Our AI-accelerated pipeline spans oncology, autoimmune, and neurodegenerative diseases — each program powered by the BioIgnis.ai computational engine.
| Program | Indication | Modality | Discovery | Lead Opt | IND-Enabling | Phase I |
|---|---|---|---|---|---|---|
| BI-101 | Solid Tumors (NSCLC) | Small Molecule | ||||
| BI-202 | Rheumatoid Arthritis | Bispecific Ab | ||||
| BI-303 | Alzheimer's Disease | ADC | ||||
| BI-404 | Triple-Neg Breast Cancer | RNA Therapeutic | ||||
| BI-505 | Inflammatory Bowel Disease | Small Molecule | ||||
| BI-606 | Parkinson's Disease | Gene Therapy |
Q1 2026BI-101 IND Filing
First AI-discovered target enters regulatory submission for NSCLC.
Q2 2026Platform v3.0
Next-gen molecular generation engine with enhanced ADMET accuracy.
Q3 2026Series B Close
Expansion into cell therapy and bispecific antibody modalities.
Q4 2026First-in-Human
BI-101 enters Phase I — our first compound to reach patients.
The Engine
BioIgnis.ai — Purpose-Built for Drug Discovery at Scale
Our computational platform integrates multi-omics analysis, causal inference, generative chemistry, and high-throughput virtual screening into one seamless workflow.
Target Discovery
Knowledge Graph + Causal Engine
Multi-omics knowledge graph with causal pathway analysis, target scoring, and druggability assessment.
Molecular Design
Generative Chemistry Studio
3D-aware generation, multi-objective optimization, and retrosynthesis route planning in one interface.
Virtual Screening
Ultra-Large Library Docking
Billions of compounds screened with physics-informed scoring and active learning-driven hit expansion.
Safety Profiling
41-Property ADMET Suite
Comprehensive in silico absorption, distribution, metabolism, excretion, and toxicity prediction.
BioIgnis.com tells the story. BioIgnis.ai delivers the science. When you're ready to move from vision to action, the platform is one click away — a high-performance computational environment built for drug discovery at scale.
Trust & Governance
Built on Rigor. Secured by Design.
Every breakthrough must stand on a foundation of trust. Our IP strategy, regulatory infrastructure, and data security architecture are designed to give partners and investors absolute confidence.
Intellectual Property
Multi-layered patent families covering AI model architectures, novel molecular entities, and platform methodologies — filed across all major jurisdictions with freedom-to-operate analysis built into every program.
Regulatory Infrastructure
FDA/EMA-aligned development processes with integrated quality management systems. GxP-compliant data handling and full computational audit trails for every prediction that supports a regulatory submission.
Data Security & Isolation
SOC 2 Type II certified infrastructure with end-to-end encryption at rest and in transit. Isolated compute environments for partner data. HIPAA-compliant handling of all clinical and patient-derived datasets.
Partnering
Accelerate Your Pipeline
We work with pharmaceutical companies, biotech firms, and academic institutions to apply our AI platform to your therapeutic programs.
Co-Discovery
Joint target identification combining BioIgnis AI with your disease biology. Shared IP, flexible licensing.
Platform Licensing
Access BioIgnis.ai as a service — dedicated compute, custom models, integration with your existing infrastructure.
Technology Out-Licensing
License our AI-discovered compounds and validated targets with comprehensive data packages and clear FTO.
The future of medicine begins with a single spark of insight.
Let's explore how BioIgnis can accelerate your drug discovery pipeline.